-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 14, BeiGene issued an announcement stating that it had signed a cooperation with Wei Li Zhibo to introduce a global R&D and production license for the LAG-3 antibody LBL-007 under research from the latter, as well as an exclusive business outside of China.
Rights
.
According to the agreement, Wei Li Zhibo will receive an advance payment of 30 million US dollars, and after reaching clinical development, drug regulatory approval and sales milestones, it will be eligible to receive a total transaction amount of up to 742 million US dollars, and double digits in authorized regions Graded sales royalties
.
In fact, it has long been common in the industry that domestic pharmaceutical companies enhance their innovation capabilities by introducing new foreign drugs
.
The industry believes that this is due to the high R&D investment, high risk, and long return period in new drug research and development
.
Therefore, in recent years, the country has vigorously promoted pharmaceutical innovation, and consistent evaluation, centralized procurement and other medical reform policies have continued to deepen.
In order to solve the dilemma of insufficient innovation, more and more domestic pharmaceutical companies have begun to "authorize introduction" Mode to introduce innovative projects to further enrich the product line
.
For example, on November 4, Shanghai Pharmaceuticals issued an announcement stating that its subsidiary Shanghai Shangyao Xinya Pharmaceutical Co.
, Ltd.
and Phagelux Inc.
(Phagelux.
Inc) signed a "cooperation agreement" for no more than US$50.
5 million (except for In addition to sales commission), the transaction amount obtained the right to develop, produce, register, distribute, sell, market, promote and sublicense the new anti-bacterial infection drug ClyO project in Mainland China, Hong Kong and Macau
.
On October 21, Luoxin Pharmaceutical issued an announcement that the company's subsidiary Shandong Luoxin and Austria Marinomed Biotech AG ("Marinomed") signed a "license agreement", Shandong Luoxin will obtain Budesolv® budesonide solution nasal spray Exclusive development, production and commercialization rights in the Greater China Region (including Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan Region)
.
The industry believes that the cooperation will help to further enrich Luoxin Pharmaceutical's product line and consolidate the company's dominant position in the field of respiratory diseases
.
On October 12, Hansen Pharmaceuticals announced that the company OliXPharmaceuticals has reached an agreement to discover, develop and commercialize siRNA therapies for key targeted indications in China
.
According to the agreement, OliXPharmaceuticals will receive an advance payment of 6.
5 million US dollars, and up to 450 million US dollars of important milestone payments and franchise license sharing
.
Subsequently, Hansen Pharmaceuticals announced the cooperation with SilenceTherapeuticsplc.
The two parties will use SilenceTherapeuticsplc's exclusive mRNAiGOLD™ platform to jointly develop siRNA drugs for three targets
.
According to the agreement, SilenceTherapeutics will receive an upfront payment of US$16 million and is eligible for additional development, regulatory and commercial milestone payments of up to US$1.
3 billion
.
According to incomplete statistics, as of September this year, the number of domestic innovative drug license in projects has exceeded 90, of which more than 30 transactions exceeded 100 million US dollars, and 14 exceeded 300 million US dollars
.
From the above overall point of view, license in has obviously become one of the rapid development methods for many innovative pharmaceutical companies
.
It is expected that as the country continues to vigorously promote the development of innovative drugs, this will also make the "authorized introduction" model of innovative drugs continue to gain popularity
.
However, it should be noted that the industry has also proposed that although the introduction of a new drug model can quickly expand the product pipeline, the lcense in model is only a convenient way to expand the product pipeline.
It cannot be relied on for a long time.
Pharmaceutical companies still need to have independent research and development capabilities
.
In the future, only companies with continuous R&D capabilities and true innovation capabilities will gain more recognition from the capital market
.
Rights
.
According to the agreement, Wei Li Zhibo will receive an advance payment of 30 million US dollars, and after reaching clinical development, drug regulatory approval and sales milestones, it will be eligible to receive a total transaction amount of up to 742 million US dollars, and double digits in authorized regions Graded sales royalties
.
In fact, it has long been common in the industry that domestic pharmaceutical companies enhance their innovation capabilities by introducing new foreign drugs
.
The industry believes that this is due to the high R&D investment, high risk, and long return period in new drug research and development
.
Therefore, in recent years, the country has vigorously promoted pharmaceutical innovation, and consistent evaluation, centralized procurement and other medical reform policies have continued to deepen.
In order to solve the dilemma of insufficient innovation, more and more domestic pharmaceutical companies have begun to "authorize introduction" Mode to introduce innovative projects to further enrich the product line
.
For example, on November 4, Shanghai Pharmaceuticals issued an announcement stating that its subsidiary Shanghai Shangyao Xinya Pharmaceutical Co.
, Ltd.
and Phagelux Inc.
(Phagelux.
Inc) signed a "cooperation agreement" for no more than US$50.
5 million (except for In addition to sales commission), the transaction amount obtained the right to develop, produce, register, distribute, sell, market, promote and sublicense the new anti-bacterial infection drug ClyO project in Mainland China, Hong Kong and Macau
.
On October 21, Luoxin Pharmaceutical issued an announcement that the company's subsidiary Shandong Luoxin and Austria Marinomed Biotech AG ("Marinomed") signed a "license agreement", Shandong Luoxin will obtain Budesolv® budesonide solution nasal spray Exclusive development, production and commercialization rights in the Greater China Region (including Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan Region)
.
The industry believes that the cooperation will help to further enrich Luoxin Pharmaceutical's product line and consolidate the company's dominant position in the field of respiratory diseases
.
On October 12, Hansen Pharmaceuticals announced that the company OliXPharmaceuticals has reached an agreement to discover, develop and commercialize siRNA therapies for key targeted indications in China
.
According to the agreement, OliXPharmaceuticals will receive an advance payment of 6.
5 million US dollars, and up to 450 million US dollars of important milestone payments and franchise license sharing
.
Subsequently, Hansen Pharmaceuticals announced the cooperation with SilenceTherapeuticsplc.
The two parties will use SilenceTherapeuticsplc's exclusive mRNAiGOLD™ platform to jointly develop siRNA drugs for three targets
.
According to the agreement, SilenceTherapeutics will receive an upfront payment of US$16 million and is eligible for additional development, regulatory and commercial milestone payments of up to US$1.
3 billion
.
According to incomplete statistics, as of September this year, the number of domestic innovative drug license in projects has exceeded 90, of which more than 30 transactions exceeded 100 million US dollars, and 14 exceeded 300 million US dollars
.
From the above overall point of view, license in has obviously become one of the rapid development methods for many innovative pharmaceutical companies
.
It is expected that as the country continues to vigorously promote the development of innovative drugs, this will also make the "authorized introduction" model of innovative drugs continue to gain popularity
.
However, it should be noted that the industry has also proposed that although the introduction of a new drug model can quickly expand the product pipeline, the lcense in model is only a convenient way to expand the product pipeline.
It cannot be relied on for a long time.
Pharmaceutical companies still need to have independent research and development capabilities
.
In the future, only companies with continuous R&D capabilities and true innovation capabilities will gain more recognition from the capital market
.
